Nuklearmedizin. Nuclear medicine最新文献

{"title":"Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck.","authors":"Sophie C Siegmund, Sebastian E Serfling, Takahiro Higuchi, Andreas Buck, Martin Canis, Christoph A Reichel, Rudolf A Werner","doi":"10.1055/a-2800-7670","DOIUrl":"10.1055/a-2800-7670","url":null,"abstract":"<p><strong>Aim: </strong>This review aims to explore the evolving field of theranostics in oncology, focusing on its potential application to head and neck squamous cell carcinoma (HNSCC). Specifically, it examines the integration of molecular imaging and radionuclide therapy in the context of theranostics.</p><p><strong>Methods: </strong>A comprehensive review of current literature was conducted to evaluate the state-of-the-art theranostic approaches in HNSCC. The review includes an analysis of established and emerging molecular targets relevant to HNSCC, as well as the potential for future theranostic developments.</p><p><strong>Results: </strong>The integration of theranostic principles into head and neck oncology is gaining momentum, with increasing interest in novel targets in the context of theranostics. Although [¹⁸F]FDG PET/CT still remains the dominant imaging modality in HNSCC, the application of novel radiotracers for imaging and radionuclide therapy holds considerable promise.</p><p><strong>Conclusion: </strong>Theranostics represents a promising future for head and neck oncology, offering the potential for personalized, biology-driven diagnostic and therapeutic strategies. While many emerging approaches are still under investigation, the combination of molecular imaging and targeted radionuclide therapy may significantly enhance the treatment of HNSCC, providing more precise and effective patient care in the future.1.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"217-222"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral absent brown adipose tissue activity and diaphragmatic paralysis allowing precise delineation of lymphoma-associated nerve damage.","authors":"Asif Moin, Elif Yilmaz, Orhan K Öz, Steven P Rowe","doi":"10.1055/a-2821-8949","DOIUrl":"10.1055/a-2821-8949","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"196-198"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147489206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 3.0.","authors":"Henryk Barthel, Matthias Brendel, Nathalie Albert, Henning Boecker, Caroline Bouter, Joachim Brumberg, Ralph Buchert, Christian La Fougère, Gerhard Gründer, Swen Hesse, Torsten Kuwert, Catharina Lange, Karl J Langen, Philipp Lohmann, Philipp T Meyer, Isabelle Miederer, Bernd Neumaier, Axel Rominger, Mathias Schreckenberger, Jörg B Schulz, Igor Yakushev, Alexander Drzezga","doi":"10.1055/a-2784-7335","DOIUrl":"10.1055/a-2784-7335","url":null,"abstract":"<p><strong>Preamble: </strong>This represents a substantial development of the guideline on the topic first published in 2016. The following notable points have been updated: the sections on background information; the clinical benefit of the method; the resulting differential diagnostic considerations; the outlook for possible future extensions of the indication spectrum; the quantitative analysis of the PET images; the embedding of the method in diagnostic pathways; and the relation to alternative biomarker methods such as amyloid measurement in CSF/blood.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"65 3","pages":"223-235"},"PeriodicalIF":1.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147990488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late post-treatment 131I SPECT/CT reveals additional lymph node metastasis of papillary thyroid carcinoma.","authors":"Erik Karaskiwiecz, Arba Syka, Felix M Mottaghy, Susanne Lütje","doi":"10.1055/a-2852-9891","DOIUrl":"10.1055/a-2852-9891","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Massive Functioning Hepatic Metastasis from Follicular Thyroid Carcinoma under Radioiodine Therapy.","authors":"John Volkenandt, Anne Popp, Claudia Brogsitter, Ralph Alexander Bundschuh","doi":"10.1055/a-2843-3860","DOIUrl":"10.1055/a-2843-3860","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147694476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT diagnosis and follow-up of arterial intimal sarcoma of the left atrium.","authors":"Tao-Tao Sun, Lin-Bo Zhu, Lei Jiang, En-Tao Liu","doi":"10.1055/a-2784-7275","DOIUrl":"https://doi.org/10.1055/a-2784-7275","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"65 2","pages":"93-96"},"PeriodicalIF":1.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioactive Gold Isotopes in the Era of Theranostics: Medical Potential of ¹⁹⁸Au and ¹⁹⁹Au Radioisotopes.","authors":"Punita Bhardwaj, Guilhem Claude, Winfried Brenner, Sarah Spreckelmeyer","doi":"10.1055/a-2784-7716","DOIUrl":"10.1055/a-2784-7716","url":null,"abstract":"<p><p>Radioactive gold isotopes, particularly the element-matched theranostic pair ¹⁹⁸Au and ¹⁹⁹Au, hold significant promise for targeted radionuclide therapy and SPECT imaging. This review critically evaluates their medical potential by contextualizing historical development, nuclear properties, production physics, radiochemical separations, and contemporary radiopharmaceutical applications to identify pathways for clinical translation.We comprehensively surveyed literature on gold isotope decay characteristics, reactor and accelerator based production from Au, Pt, and Hg targets, purification strategies including ion-exchange chromatography, solid-phase extraction, polymer/zeolite adsorption, and liquid-liquid extraction, alongside reviewing a spectrum of ¹⁹⁸Au/¹⁹⁹Au radiotracers from small-molecule complexes to nanostructures and bioconjugates. ¹⁹⁸Au and ¹⁹⁹Au offer complementary β^- emissions for therapy and their γ photons are ideal for SPECT imaging, with scalable carrier-added production routes from ¹⁹⁷Au and non-carrier-added routes via enriched Pt/Hg. Robust separation techniques deliver radioactive gold with higher purity, enabling the production of diverse agents including but not limited to Au(III) Schiff-bases, phosphine/dithiocarbamate/NHC complexes, thioglucose derivatives, intrinsically doped nanoparticles (RGD-, bombesin-, HER2-targeted), and antibody conjugates.While radioactive gold research has progressed from colloidal ¹⁹⁸Au brachytherapy to modern small molecule based complexes, barriers persist in sustainable high-specific-activity production, target recycling, in vivo stability, and clinical validation. Nevertheless, gold's chemical and physical characteristics position ¹⁹⁸Au/¹⁹⁹Au as candidates for next-generation radio-theranostics.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"69-82"},"PeriodicalIF":1.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear cardiology - Current status of the clinical application.","authors":"Oliver Lindner, Christian Goetz, Frank M Bengel, Axel Linke, Alexander Maier, Maria Papathanasiou, Sigmund Silber, Christoph Rischpler, Simon Greulich, Jan Bucerius","doi":"10.1055/a-2778-2169","DOIUrl":"10.1055/a-2778-2169","url":null,"abstract":"<p><p>This updated position paper from the German Society of Nuclear Medicine (DGN) and the German Cardiac Society (DGK) replaces the original statement from 2018. It gives an overview of the fields of application and the current value of nuclear cardiological imaging. The topics covered include chronic coronary syndrome, including viability diagnostics and the special value of positron emission tomography (PET), cardiomyopathies, cardiac sarcoidosis, amyloidosis, infectious endocarditis and inflammation of cardiac implants.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"52-59"},"PeriodicalIF":1.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145992520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.","authors":"Christian Schütze, Markus Borowski, Martin Freesmeyer, Robert Freudenberg, Heribert Hänscheid, Jens Kurth, Marc Rudi Linde, Lara-Christiane Militzer, Bernhard Sattler, Tabea Nikola Schmidt, Paul Soubiran, Mathias Steffner, Lars Stegger, Carsten Wanke, Christian Kühnel","doi":"10.1055/a-2784-7468","DOIUrl":"10.1055/a-2784-7468","url":null,"abstract":"<p><p>The study investigated routinely used radiopharmaceuticals containing lutetium-177 (¹⁷⁷Lu), providing reference values for their effective half-life (T_1/2,eff). So far, no guidelines regarding discharging this patients exist, are essential to ensure radiation protection of the public. This study contributes to the development of binding discharge criteria regarding ¹⁷⁷Lu therapies.This retrospective multicenter study comprised eight nuclear medicine departments. Two commercially available products and two in-house preparations were considered. Radiation measurement methods, in terms of measuring device, setup, and time points were reported, as well as dose rate measurements for T_1/2,eff calculation.The study includes 210 dose rate measurement sets with a mean administered activity of (7149 ± 522) MBq. When only measurements up to 48 h p.i. were taken into account the T_{1/2, eff} were shorter (Pluvicto 1.30 d, Lutathera 1.40 d, ihPSMA 1.45 d, ihRRT 1.97 d) compared to 168 h (1.60 d, 1.89 d, 2.10 d, and 2.85 d, respectively). Differences were statistically significant for all compounds except Lutathera. The 90^th percentile of the T_1/2,eff observed in late measurements (Pluvicto 2.0 d, Lutathera 3.0 d, ihPSMA 3.5 d, ihRRT 4.0 d) can be considered conservative values for discharge calculations.The T_1/2,eff of ¹⁷⁷Lu is considerably shorter than its T_1/2,phy, owing to the pharmacokinetics of the entire molecule. This highlights the need of considering biological clearance mechanisms into calculations of discharge times for patients treated with ¹⁷⁷Lu. If direct measurements are not feasible in clinical routine, reference values support inpatient planning while ensuring radiation protection.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"60-68"},"PeriodicalIF":1.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Difficult-to-interpret dopamine transporter SPECT with [123I]ioflupane in the diagnosis of parkinsonism.","authors":"Ivayla Ilieva Apostolova, Thomas Buddenkotte, Loren Jedid, Susanne Klutmann, Rickmer Braren, Philipp T Meyer, Ralph Buchert","doi":"10.1055/a-2784-7591","DOIUrl":"10.1055/a-2784-7591","url":null,"abstract":"<p><p>To estimate (i) the rate of difficult-to-interpret cases in dopamine transporter (DAT)-SPECT with [¹²³I]ioflupane and (ii) the diagnostic accuracy of binary visual categorization in difficult-to-interpret DAT-SPECT.The study included 178 control subjects (49% females, 63.7±11.7y) and 178 sex- and age-matched patients with pre-screening clinical diagnosis of Parkinson's disease (PD) from the Parkinson's Progression Markers Initiative (PPMI). SPECT images reconstructed by the PPMI and a local method were visually interpreted twice by 2 independent readers with respect to Parkinson-like reduction of the striatal signal using the following 6-score: -3 = clearly reduced, -2 = probably reduced, -1 = more likely reduced than normal, 1 = more likely normal than reduced, 2 = probably normal, 3 = clearly normal. Cases with 6-score of -1 or 1 were considered \"difficult-to-interpret\", all other cases were considered \"conclusive\". To assess diagnostic accuracy relative to the clinical group label (control, PD), the 6-score was binarized using 0 as cutoff.The proportion of difficult-to-interpret cases ranged between 3.4% (95%-CI 1.5-5.2%) and 7.6% (4.8-10.3%) across readers and reconstruction methods. The proportion of cases misclassified by the binarized score ranged between 17.4% (1.9-32.9%) and 50.0% (25.5-74.5%) among the difficult-to-interpret cases, and between 5.1% (2.7-7.4%) and 6.4% (3.8-9.0%) among the conclusive cases.(i) the proportion of difficult-to-interpret cases in DAT-SPECT for the diagnosis of parkinsonism is not larger than 10%, (ii) the diagnostic accuracy of binary decisions is severely reduced in these cases. We therefore recommend reporting difficult-to-interpret cases as \"inconclusive\", unless in special situations.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"65 2","pages":"83-92"},"PeriodicalIF":1.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147611001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}